| request information: |
|
| Catalog Code: | NB120-10516 |
| Product Name: | TRAIL Antibody |
| Product Description: | Mouse Monoclonal anti-TRAIL (75411.11) |
| Clone: | 75411.11 |
| Clonality: | Monoclonal |
| ListPrice: | 295 |
| Immunogen: | Recombinant full length protein (Human). |
| Specificity: | In immunoblots, this antibody demonstrates approximately 5% cross-reactivity with recombinant human Trance and recombinant human TNF alpha. |
| Cross Reactivity: | Cross-reacts with Human. |
| Packaging: | 0.1 mg Tissue culture supernatant. |
| Uses: | ELISA and western blot. ELISA dilution determined using 25ng/well recombinant human TRAIL. Western blot detects a band of approximately 24 kDa (predicted molecular weight: 33.7 kDa). Determined using human TRAIL at approximately 50 ng/lane under non-reducing and reducing conditions. Inhibition: Monoclonal anti-TRAIL neutralizes bioactivity on mouse L929 cells. To measure the ability of this antibody to neutralize the biological activity of TRAIL, cross-linked recombinant human TRAIL is incubated with various concentrations of the antibody for 1 hour at 37C. |
| Localization: | Cell Membrane |
| Background: | Apoptosis or programmed cell death is induced in cells by a group of death domain containing receptors. Binding of ligand to these receptors sends signals that activate members of the caspase family of proteases. The signals ultimately cause degradation of chromosomal DNA by activating DNase. TRAIL (TNF related apoptosis induced ligand) or Apo 2L initiates apoptosis of tumor cells by binding to either of its receptors, DR4 or DR5. These receptors consist of an extracellular TRAIL binding domain and a cytoplasmic "death domain". In addition, two decoy receptors for TRAIL have also been identified. These receptors, designated DcR1 and DcR2, lack the death domain. Binding of TRAIL to either of these receptors, therefore, does not transmit the death signal. Thus, these receptors represent a novel way of regulating cell sensitivity to a pro-apoptotic cytokine at the cell surface. TRAIL is expressed predominantly in spleen, lung, and prostate but also in many other tissues. TRAIL is a type II membrane protein from the TNF family. The human form of the protein is 281 amino acids in length, whereas the murine form is 291 amino acids. The two forms share 65% identity. Recombinant human TRAIL monomer has a molecular mass of approximately 21 kDa. Due to glycosylation, recombinant human TRAIL migrates as a 24 kDa protein in SDS PAGE. |
| Purity: | Tissue culture supernatant |
| Isotype: | IgG1 |
| Host Name: | Mouse |
| Buffer: | 0.01M Na phosphate, 0.25M NaCl, pH7.6, , 0.01% Thimerisol, 15mg/ml BSA |
| Application Summary: | ELISA 0.5-1 ug/ml, Western Blot 1-2 ug/ml, Functional , Other |
| Species Summary: | Hu, |
| Alternate Names: | anti-Apo 2 ligand antibody, anti-Apo 2L antibody, anti-APO2L antibody, anti-CD253 antibody, anti-TL2 antibody, anti-TNF Related Apoptosis Inducing Ligand antibody, anti-TNFSF10 antibody, anti-TRAIL antibody, anti-TRAIL PEN antibody, anti-Tumor Necrosis Factor (ligand) Superfamily Member 10 antibody |
| Package Size: | 0.1 mg |
| Preservative: | 0.05% sodium azide |
| General References: | MacFarlane M et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 272:25417-20 (1997). <PUBMED:9325248> Pan G et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-8 (1997). <PUBMED:9242610> Pan G et al. The receptor for the cytotoxic ligand TRAIL. Science 276:111-3 (1997). <PUBMED:9082980> Pitti RM et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-90 (1996). <PUBMED:8663110> |
order or
more information: | company product webpage |
|